-+ 0.00%
-+ 0.00%
-+ 0.00%

EDAP publishes HIFI-2 trial data backing Focal One HIFU in radiorecurrent prostate cancer

PUBT·04/30/2026 12:40:52
Listen to the news
EDAP publishes HIFI-2 trial data backing Focal One HIFU in radiorecurrent prostate cancer
  • Edap TMS reported publication of HIFI-2, a large prospective multicenter study of Focal One robotic HIFU in prostate cancer that returned in prostate following radiotherapy.
  • Results were presented as final outcomes in European Urology Oncology, not flagged for a future conference readout.
  • Study supported meaningful disease control while preserving quality of life, positioning salvage HIFU as an organ-sparing option for selected patients.
  • Edap framed data as supportive of broader clinical adoption, citing existing guideline recognition for HIFU in this setting.
  • Company also pointed to Medicare coverage in radiorecurrent use, strengthening reimbursement backdrop for Focal One commercialization.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edap TMS SA published the original content used to generate this news brief on April 30, 2026, and is solely responsible for the information contained therein.